<DOC>
	<DOCNO>NCT00519181</DOCNO>
	<brief_summary>Reversible acetylation histone tail play important role control specific gene expression . Mounting evidence establish histone deacetylase inhibitor Valproic Acid ( VPA ) selectively induce cellular differentiation apoptosis variety cancer cell . In single-center , one year open-label trial , 19 HAM/TSP patient treat oral dos VPA ( 20mg/Kg/day ) . Primary end-points therapeutic safety effect HTLV-1 proviral load ( significant sustain decrease expect ) . Secondary end-point neurological status one-year treatment .</brief_summary>
	<brief_title>Safety Efficiency Study Valproic Acid In HAM/TSP</brief_title>
	<detailed_description />
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Paraparesis , Tropical Spastic</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>HAM/TSP patient diagnose WHO criterion Obtained informed consent . Patients hepatic nephrologic disease Valproic Acid allergy Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HTLV</keyword>
	<keyword>HAM/TSP</keyword>
	<keyword>VALPROIC ACID</keyword>
	<keyword>PROVIRAL LOAD</keyword>
</DOC>